has received FDA approval for its Fluticasone Propionate Nasal Spray USP, marking the company's first nasal spray entry into the US OTC market. The bioequivalent product targets the substantial $384.7 million allergy relief market, with commercial launch planned for April 2026 through Glenmark Therapeutics Inc., USA. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.